Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1245/s10434-012-2782-8 http://scihub22266oqcxt.onion/10.1245/s10434-012-2782-8 C4504423!4504423!23456376     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23456376&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Surg+Oncol 2013 ; 20 (4): 1121-7 Nephropedia Template TP {{tp|p=23456376|t=2013. Isolated Limb Infusion in a Series of over 100 Infusions, a Single Center Experience |pdf=|usr=}}{{23456376}} gab.com Text Isolated Limb Infusion in a Series of over 100 Infusions, a Single Center Experience JO: Ann Surg Oncol http://www.kidney.de/pget.php?&tw=1&pmid=23456376 #FOAvip Introduction: Isolated limb infusion (ILI) is a therapeutic option for patients with recurrent, unresectable extremity malignancies. Methods: A prospectively collected single institution database of patients undergoing ILI was analyzed for preoperative, intraoperative, and postoperative parameters and outcomes. Results: From 5/2007-1/2012, 76 patients successfully underwent initial ILI, and 28 following either previous hyperthermic isolated limb perfusion (HILP) or ILI. Seventy-nine (74%) patients had melanoma, 24 (22%) sarcoma, 3 (3%) Merkel cell and 1 (1%) squamous cell carcinoma. There were 55 (72%) initial and 22 (79%) repeat lower extremity (LE) ILI?s, and 21 (78%) initial and 6 (22%) repeat upper extremity (UE) ILI?s. Serologic toxicity, measured by serum creatine kinase (CK), peaked higher and later in LE ILI?s, median 620 vs. 124 IU/L and postoperative day 4 vs. 2, respectively, P<0.05. LE ILI?s had a longer hospital length of stay (LOS), median 6 vs. 5 days (P<0.0001). A median of grade II Wieberdink regional toxicity was observed. Three-month follow-up was available in 94 (90%). A response (ORR) was seen in 72% of ILI?s performed for melanoma and 58% for sarcoma. No difference in response was observed between UE vs. LE or between initial vs. repeat ILI?s. Repeat UE ILI?s, however, appeared to have an improved ORR than repeat LE ILI?s, 83% vs. 64%. Conclusion: ILI may be successfully performed for cutaneous and soft tissue malignancies. LE ILI?s have higher CK levels and slightly longer LOS. Repeat ILI?s are not associated with increased toxicity and similar ORR. UE ILI?s may have better overall response rates. Twit Text FOAVip Isolated Limb Infusion in a Series of over 100 Infusions, a Single Center Experience ????Ann Surg Oncol http://www.kidney.de/pget.php?&tw=1&pmid=23456376 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23456376 #FOAvip English Wikipedia <ref>{{Cite pmid|23456376}}</ref> Isolated Limb Infusion in a Series of over 100 Infusions, a Single Center Experience #MMPMID23456376 Wong J; Chen YA; Fisher KJ; Zager JS Ann Surg Oncol 2013[Apr]; 20 (4): 1121-7 PMID23456376show ga Introduction: Isolated limb infusion (ILI) is a therapeutic option for patients with recurrent, unresectable extremity malignancies. Methods: A prospectively collected single institution database of patients undergoing ILI was analyzed for preoperative, intraoperative, and postoperative parameters and outcomes. Results: From 5/2007-1/2012, 76 patients successfully underwent initial ILI, and 28 following either previous hyperthermic isolated limb perfusion (HILP) or ILI. Seventy-nine (74%) patients had melanoma, 24 (22%) sarcoma, 3 (3%) Merkel cell and 1 (1%) squamous cell carcinoma. There were 55 (72%) initial and 22 (79%) repeat lower extremity (LE) ILI?s, and 21 (78%) initial and 6 (22%) repeat upper extremity (UE) ILI?s. Serologic toxicity, measured by serum creatine kinase (CK), peaked higher and later in LE ILI?s, median 620 vs. 124 IU/L and postoperative day 4 vs. 2, respectively, P<0.05. LE ILI?s had a longer hospital length of stay (LOS), median 6 vs. 5 days (P<0.0001). A median of grade II Wieberdink regional toxicity was observed. Three-month follow-up was available in 94 (90%). A response (ORR) was seen in 72% of ILI?s performed for melanoma and 58% for sarcoma. No difference in response was observed between UE vs. LE or between initial vs. repeat ILI?s. Repeat UE ILI?s, however, appeared to have an improved ORR than repeat LE ILI?s, 83% vs. 64%. Conclusion: ILI may be successfully performed for cutaneous and soft tissue malignancies. LE ILI?s have higher CK levels and slightly longer LOS. Repeat ILI?s are not associated with increased toxicity and similar ORR. UE ILI?s may have better overall response rates. äIsolated Limb Infusion in a Series of over 100 Infusions, a Single Cen(epmc).pdf DeepDyve Pubget Overpricing